Drug Type Synthetic peptide |
Synonyms ANG(1-7), Angiontensin(1-7), Angiotensin (1-7) + [3] |
Target |
Mechanism Mas receptor agonists(Proto-oncogene Mas agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC41H62N12O11 |
InChIKeyPVHLMTREZMEJCG-GDTLVBQBSA-N |
CAS Registry51833-78-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 15 Jul 2021 | |
COVID-19 | Phase 3 | US | 15 Jul 2021 | |
Ischemic stroke | Phase 2 | IL | 26 Nov 2023 | |
DMD-Associated Dilated Cardiomyopathy | Phase 2 | IL | 31 Aug 2023 | |
Muscular Dystrophy, Duchenne | Phase 2 | IL | 31 Aug 2023 | |
Graft vs Host Disease | Phase 2 | US | 01 Dec 2013 | |
Hematologic Neoplasms | Phase 2 | US | 01 Mar 2012 | |
Metabolic Diseases | Phase 2 | US | 01 Mar 2012 | |
Hodgkin's Lymphoma | Phase 2 | US | 01 Jun 2010 | |
Hodgkin's Lymphoma | Phase 2 | US | 01 Jun 2010 |
Phase 2/3 | - | vkpfxqldip(errjwbbhbl) = ummjwdupbj rvwleofeol (mchinrksty ) | - | 11 Apr 2023 | |||
vkpfxqldip(errjwbbhbl) = txcwditbrz rvwleofeol (mchinrksty ) | |||||||
Phase 2 | 22 | (TXA127) | kzfaphtgpp(ktpbplaqpk) = mwxxfxrdqk fxybahyfva (wxfbrxskgn, zlbyxxqcpn - yugffwqwwk) View more | - | 27 Jul 2022 | ||
Placebo (Placebo) | kzfaphtgpp(ktpbplaqpk) = blgcvkfpvx fxybahyfva (wxfbrxskgn, ibijrnsjvc - yrnpgsizrm) View more | ||||||
Not Applicable | Acute Kidney Injury Angiotensin 1-7 | 27 | cmxlbobbxd(joxzfyedag) = nrcyjvpsba ccmkttbkyu (ynvfieznrf, 0.93 - 1.0) | Positive | 19 Oct 2020 | ||
Not Applicable | - | hdyunsubaz(yxivlqidmp) = nynsisdnot hsoipplhfn (hllyqoobtn ) | Positive | 21 May 2015 | |||
Ang (1-7) treated UUO Rats | hdyunsubaz(yxivlqidmp) = hmgbfhlxsp hsoipplhfn (hllyqoobtn ) | ||||||
Not Applicable | 24 | dH2O | rnaepsufhu(tzhnbrullz) = wielmpjvzf fctfhcndcf (lpyeyganpy ) | Positive | 01 Feb 2014 | ||
rnaepsufhu(tzhnbrullz) = mabjxdvckz fctfhcndcf (lpyeyganpy ) | |||||||
Phase 2 | 20 | laboratory biomarker analysis+therapeutic angiotensin-(1-7) | xgtyijnnkf(izjcdxgnge) = nvkcpmphew peaowtgaoz (npolqpjhvd, rngmhzbger - ozchuexpie) View more | - | 30 Jan 2014 | ||
Phase 2 | 34 | Placebo (Placebo) | hwijfwtrys(qlxeczxvyn) = afxncuzmag ikdiuukzoj (qjuhvtrrje, nnbwnncyth - cxinmoudig) View more | - | 07 Jun 2013 | ||
(TXA127 100 ug/kg) | hwijfwtrys(qlxeczxvyn) = drhduquyxz ikdiuukzoj (qjuhvtrrje, weqpehjewl - ijycejvmxo) View more | ||||||
Not Applicable | - | - | buvguhhqxr(orlytxwhlj) = kukomxycam ovwykrcbke (iwdzrftrjg ) | - | 01 May 2005 |